Results 191 to 200 of about 29,575 (253)
Background Non–small cell lung cancer (NSCLC), accounting for 80% of lung cancer cases, remains a leading cause of cancer‐related mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes, their efficacy is limited to a subset of patients, necessitating robust biomarkers for personalized immunotherapy response prediction ...
Shuqi Wu +22 more
wiley +1 more source
Prognostic role and mutational characteristics of N6-methyladenosine-related genes in lung adenocarcinoma. [PDF]
Yang J, Chu X, Chen Z, Long Y, Chen J.
europepmc +1 more source
The latest progression of N6-methyladenosine (m<sup>6</sup>A) RNA modification in diabetes mellitus and diabetic complications. [PDF]
Yin G +5 more
europepmc +1 more source
A New N6-Methyladenosine Inhibitor, Celastrol, Alleviates Rheumatoid Arthritis via Targeting IGF2BP3. [PDF]
Geng Q +13 more
europepmc +1 more source
Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases [PDF]
core +1 more source
Regulation of viral hepatitis by N6-methyladenosine RNA methylation. [PDF]
Moon JS, Siddiqui A, Kim GW.
europepmc +1 more source
Waterpipe Smoke-Induced N6-Methyladenosine Modification Promotes the Progression of Oral Squamous Cell Carcinoma. [PDF]
Prasad P +5 more
europepmc +1 more source

